Sylvie Quaranta

647 total citations
27 papers, 403 citations indexed

About

Sylvie Quaranta is a scholar working on Oncology, Molecular Biology and Pharmacology. According to data from OpenAlex, Sylvie Quaranta has authored 27 papers receiving a total of 403 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 10 papers in Molecular Biology and 9 papers in Pharmacology. Recurrent topics in Sylvie Quaranta's work include Pharmacogenetics and Drug Metabolism (9 papers), Cancer therapeutics and mechanisms (8 papers) and HIV/AIDS drug development and treatment (6 papers). Sylvie Quaranta is often cited by papers focused on Pharmacogenetics and Drug Metabolism (9 papers), Cancer therapeutics and mechanisms (8 papers) and HIV/AIDS drug development and treatment (6 papers). Sylvie Quaranta collaborates with scholars based in France, Canada and United States. Sylvie Quaranta's co-authors include Caroline Solas, Bruno Lacarelle, Fabienne Thomas, Nicolas Simon, Romain Guilhaumou, Nicolás André, Véronique Bourgarel‐Rey, Franck Broly, Marie‐Anne Loriot and Nicolas Picard and has published in prestigious journals such as Biochemical and Biophysical Research Communications, Critical Care and British Journal of Clinical Pharmacology.

In The Last Decade

Sylvie Quaranta

26 papers receiving 390 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sylvie Quaranta France 11 181 153 123 100 83 27 403
Maria L. Alvarellos United States 9 88 0.5× 103 0.7× 160 1.3× 89 0.9× 56 0.7× 10 381
Vincent Ménard Canada 10 115 0.6× 162 1.1× 180 1.5× 66 0.7× 49 0.6× 16 398
Melanie Herzog Germany 8 211 1.2× 101 0.7× 66 0.5× 92 0.9× 128 1.5× 9 433
Melanie de la Cruz United States 6 234 1.3× 108 0.7× 55 0.4× 114 1.1× 83 1.0× 7 401
Ron van Schaik Netherlands 9 113 0.6× 104 0.7× 147 1.2× 103 1.0× 173 2.1× 29 553
Hanna Nylén Sweden 10 131 0.7× 78 0.5× 244 2.0× 69 0.7× 44 0.5× 12 423
P. Neuhaus Germany 8 202 1.1× 126 0.8× 288 2.3× 85 0.8× 131 1.6× 11 652
Nilay Thakkar United States 9 198 1.1× 117 0.8× 47 0.4× 68 0.7× 59 0.7× 17 467
Jennifer Hockings United States 9 86 0.5× 233 1.5× 132 1.1× 51 0.5× 42 0.5× 19 512
Nagdeep Giri United States 14 383 2.1× 188 1.2× 51 0.4× 118 1.2× 119 1.4× 23 633

Countries citing papers authored by Sylvie Quaranta

Since Specialization
Citations

This map shows the geographic impact of Sylvie Quaranta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sylvie Quaranta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sylvie Quaranta more than expected).

Fields of papers citing papers by Sylvie Quaranta

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sylvie Quaranta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sylvie Quaranta. The network helps show where Sylvie Quaranta may publish in the future.

Co-authorship network of co-authors of Sylvie Quaranta

This figure shows the co-authorship network connecting the top 25 collaborators of Sylvie Quaranta. A scholar is included among the top collaborators of Sylvie Quaranta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sylvie Quaranta. Sylvie Quaranta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Korchia, Théo, Mélanie Faugère, Sylvie Quaranta, et al.. (2024). CYP2D6 and CYP2C19 ultrarapid metabolisms are associated with suicide attempts in schizophrenia. L Encéphale. 51(4). 418–423.
2.
Guellec, Chantal Barin‐Le, Nicolas Picard, Laurent Becquemont, et al.. (2019). La pharmacogénétique au service du soin en France : une discipline qui évolue !. Therapies. 75(5). 459–470. 5 indexed citations
3.
4.
5.
Solas, Caroline, Sylvie Brégigeon, Sylvie Quaranta, et al.. (2017). Ledipasvir and tenofovir drug interaction in human immunodeficiency virus–hepatitis C virus coinfected patients: Impact on tenofovir trough concentrations and renal safety. British Journal of Clinical Pharmacology. 84(2). 404–409. 7 indexed citations
6.
7.
Étienne-Grimaldi, Marie-Christine, Fabienne Thomas, Sylvie Quaranta, et al.. (2015). UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice. Fundamental and Clinical Pharmacology. 29(3). 219–237. 84 indexed citations
8.
Boyer, Jean-Christophe, Marie-Christine Étienne-Grimaldi, Fabienne Thomas, et al.. (2014). Intérêt du génotypage de l’UGT1A1 dans le cadre du traitement des cancers digestifs par irinotécan. Bulletin du Cancer. 101(6). 533–553. 9 indexed citations
9.
Quaranta, Sylvie, et al.. (2014). Clinical application, limits and perspectives of pharmacogenetic and pharmacokinetic analysis of anticancer drugs. Annales de biologie clinique. 72(5). 527–542. 4 indexed citations
10.
Quaranta, Sylvie, et al.. (2014). Triazole antifungal agents: practice guidelines of therapeutic drug monitoring and perspectives in treatment optimization. Annales de biologie clinique. 72(4). 391–404. 5 indexed citations
11.
Muret, Patrice, et al.. (2011). Niveau de preuve du suivi therapeutique pharmacologique de la névirapine. Therapies. 66(3). 187–195. 3 indexed citations
12.
Roch, Antoine, Dorothée Blayac, Caroline Solas, et al.. (2011). Effect of fluid loading during hypovolaemic shock on caspofungin pharmacokinetic parameters in pig. Critical Care. 15(5). R219–R219. 7 indexed citations
13.
Guilhaumou, Romain, Caroline Solas, Véronique Bourgarel‐Rey, et al.. (2011). Impact of plasma and intracellular exposure and CYP3A4, CYP3A5, and ABCB1 genetic polymorphisms on vincristine-induced neurotoxicity. Cancer Chemotherapy and Pharmacology. 68(6). 1633–1638. 39 indexed citations
14.
Solas, Caroline, Maxime C. Paré, Sylvie Quaranta, & Françoise Stanke‐Labesque. (2011). Niveau de preuve du suivi therapeutique pharmacologique de la ribavirine. Therapies. 66(3). 221–230. 4 indexed citations
15.
Guilhaumou, Romain, Nicolas Simon, Sylvie Quaranta, et al.. (2010). Population pharmacokinetics and pharmacogenetics of vincristine in paediatric patients treated for solid tumour diseases. Cancer Chemotherapy and Pharmacology. 68(5). 1191–1198. 33 indexed citations
16.
17.
Solas, Caroline, Nicolas Simon, Sylvie Quaranta, et al.. (2007). Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV‐infected patients. British Journal of Clinical Pharmacology. 64(3). 353–362. 32 indexed citations
18.
Quaranta, Sylvie, Dany Chevalier, Véronique Bourgarel‐Rey, et al.. (2006). Identification by single-strand conformational polymorphism analysis of known and new mutations of the CYP3A5 gene in a French population. Toxicology Letters. 164(2). 177–184. 10 indexed citations
19.
Cauffiez, Christelle, Jean‐Marc Lo‐Guidice, Sylvie Quaranta, et al.. (2004). Genetic polymorphism of the human cytochrome CYP2A13 in a French population: implication in lung cancer susceptibility. Biochemical and Biophysical Research Communications. 317(2). 662–669. 30 indexed citations
20.
Cézard, Christine, et al.. (2003). Dystonies aiguës au métoclopramide chez l’enfant. Therapies. 58(4). 367–370. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Maria L. Alvarellos Breakdown of academic impact, for papers by Vincent Ménard Breakdown of academic impact, for papers by Melanie Herzog Breakdown of academic impact, for papers by Melanie de la Cruz Breakdown of academic impact, for papers by Ron van Schaik Breakdown of academic impact, for papers by Hanna Nylén Breakdown of academic impact, for papers by P. Neuhaus Breakdown of academic impact, for papers by Nilay Thakkar Breakdown of academic impact, for papers by Jennifer Hockings Breakdown of academic impact, for papers by Nagdeep Giri
Rankless by CCL
2026